Anti-Papillary renal cell carcinoma antibody

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Papillary renal cell carcinoma (PRCC) also known as papillary renal is a significant variant of kidney cancer. It arises mechanically from the epithelial cells of the kidney tubules that exhibit papillary growth patterns. PRCC lacks a single protein target but involves various changes on the molecular level often linked to genetic alterations such as mutations in the MET oncogene. These changes can affect cell surface expression and signal pathways. The mass or size data about individual protein targets in this context is not typically described due to the complex and multi-genetic nature of PRCC.

Biological function summary

PRCC forms as a type of cancer characterized by the formation of finger-like projections in the kidney. It does not align to a single protein or simple biological function but involves components like alterations in the MET pathway an independent complex soliciting increased proliferative and migratory signals within renal tissues. This process can lead to the unusual cell growth that distinguishes PRCC in affected kidneys.

Pathways

MET signaling pathway and the associated HGF (hepatocyte growth factor) signaling cascade are closely involved in papillary renal phenotypes. These pathways contribute significantly to cell growth migration and differentiation regulation within the renal system. It's related to proteins such as RAS and PI3K which play essential roles in further amplifying cellular signals that contribute to oncogenesis.

Associated diseases and disorders

PRCC is closely linked to kidney cancer specifically identified in renal cell carcinoma spectrum. Genetic evidence connects PRCC to von Hippel-Lindau (VHL) disease a disorder known to predispose individuals to various tumors. The VHL protein exhibits abnormal function in both VHL disease and PRCC highlighting its role in disease progression and potential as a therapeutic target. Additionally the involvement of the MET protein stands out as a specific player in familial cases of PRCC contributing to an inherited predisposition to this type of cancer.